Clinical Trial Update: A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating BAT3306 compared with pembrolizumab (Keytruda) in patients with non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAT3306
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: RECRUITING